From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management
1Department of Breast Medicine, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China
2Department of Pharmacology, Cancer Hospital of China Medical University, Shenyang 110042, China
3Central Laboratory, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China
4Medicine Center, Kanghui Biotechnology Inc, Shenyang 110000, China
收起